Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’...
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“Stay”) under the Companies’...
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility for continued listing on the TSX of the securities...
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement...
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List...
Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug...
- The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage...
- AAPM is the primary organization for pain medicine physicians in the U.S. Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, today announced that the...
- Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month - Phase II trial enhancements include placebo arm, increased sample size and adaptive...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.295 | 0.295 | 0.295 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.295 | 0.295 | 0.295 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.295 | 0.295 | 0.295 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.295 | 0.295 | 0.295 | 0 | 0 | CS |
| 52 | -0.635 | -68.2795698925 | 0.93 | 1.14 | 0.15 | 38127 | 0.51712376 | CS |
| 156 | -0.405 | -57.8571428571 | 0.7 | 1.23 | 0.15 | 36939 | 0.60764028 | CS |
| 260 | -0.12 | -28.9156626506 | 0.415 | 7.52 | 0.15 | 89820 | 1.85703391 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
